XPR1

Across TCGA pan-cancer cohorts, XPR1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated XPR1 data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher XPR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated XPR1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where XPR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.560	0.783	.008	22	view →
HNSC	DFS	Quartile	All	0.689	0.382	.003	18	view →
LUAD	OS	Quartile	III,IV	0.819	0.328	.020	8	view →
CCRCC	DFS	Tertile	IV	0.138	0.948	.024	6	view →
GBM	DFS	Quartile	All	0.225	0.532	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

XPR1–PDAC (DFS)

Open the PDAC breakdown →